Table 1.
Summary of efficacy of whole blood or PBMC from TS-injected mice as a radiomitigator against several doses of total-body gamma-irradiation.
| Experiment | Mobilising agent | Blood volume (µl)/PBMC # (million–M) | Transfusion time in relation to irradiation (h) | Radiation dose of recipient (Gy) | Recipient % survival at Day 30 | Statistical significance |
|---|---|---|---|---|---|---|
| 1. | TS | Blood 25 µl | +2 | 9.2 | 26 | NS |
| Blood 50 µl | +2 | 9.2 | 89 | S | ||
| Blood 100 µl | +2 | 9.2 | 84 | S | ||
| Blood 150 µl | +2 | 9.2 | 95 | S | ||
| Vehicle | Blood 150 µl | +2 | 9.2 | 5 | ||
| 2. | TS | PBMC 0.5 M | +2 | 9.2 | 84 | S |
| Vehicle | PBMC 0.5 M | +2 | 9.2 | 50 | ||
| 3. | TS | PBMC 2 M | +2 | 9.2 | 100 | S |
| Vehicle | PBMC 2 M | +2 | 9.2 | 6 | ||
| 4. | TS | PBMC 2 M | +24 | 9.2 | 88 | S |
| Vehicle | PBMC 2 M | +24 | 9.2 | 50 | ||
| 5. | TS | Blood 100 µl | +2 | 11 | 100 | S |
| Vehicle | Blood 100 µl | +2 | 11 | 31 | ||
| TS | Blood 100 µl | +24 | 11 | 88 | S | |
| Vehicle | Blood 100 µl | +24 | 11 | 13 | ||
| 6. | TS | PBMC 5 M | +2 | 11 | 100 | S |
| Vehicle | PBMC 5 M | +2 | 11 | 31 | ||
| TS | PBMC 5 M | +24 | 11 | 94 | S | |
| Vehicle | PBMC 5 M | +24 | 11 | 38 | ||
| TS | PBMC 5 M | +48 | 11 | 69 | S | |
| Vehicle | PBMC 5 M | +48 | 11 | 0 | ||
| 7. | TS | PBMC 5 M | +24 | 11.5 | 94 | S |
| Vehicle | PBMC 5 M | +24 | 11.5 | 19 | ||
| TS | PBMC 5 M | +24 | 12 | 69 | S | |
| Vehicle | PBMC 5 M | +24 | 12 | 6 | ||
| TS | PBMC 5 M | +24 | 12.5 | 38 | NS | |
| Vehicle | PBMC 5 M | +24 | 12.5 | 0 | ||
| TS | PBMC 5 M | +24 | 13 | 0 | NS | |
| Vehicle | PBMC 5 M | +24 | 13 | 0 | ||
| TS | PBMC 5 M | +24 | 14 | 0 | NS | |
| Vehicle | PBMC 5 M | +24 | 14 | 0 |
Donor mice were administered TS and AMD3100 (72 and 1 h, respectively) before blood collection. PBMCs were isolated from donor blood samples. Recipient mice (n = 16 per treatment group) were irradiated with varying doses of radiation and then transfused with whole blood or PBMCs at different times after irradiation. S indicates a significant difference between the TS-treated group and the respective vehicle. NS indicates no significant difference.